Identification of High-Affinity
P2Y<sub>12</sub> Antagonists
Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone
- Publication date
- Publisher
Abstract
A series of novel, highly potent P2Y<sub>12</sub> antagonists
as
inhibitors of platelet aggregation based on a phenylpyrazole glutamic
acid piperazine backbone is described. Exploration of the structural
requirements of the substituents by probing the structure–activity
relationship along this backbone led to the discovery of the <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide moiety
as a highly privileged motif. Combining the most favorable substituents
led to remarkably potent P2Y<sub>12</sub> antagonists displaying not
only low nanomolar binding affinity to the P2Y<sub>12</sub> receptor
but also a low nanomolar inhibition of platelet aggregation in the
human platelet rich plasma assay with IC<sub>50</sub> values below
50 nM. Using a homology and a three-dimensional quantitative structure–activity
relationship model, a binding hypothesis elucidating the impact of
several structural features was developed